Epiberberine

• UNSPSC Description:

  Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC50s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO- scavenging effect (IC50, 16.83 μM), and can be used for the research of Alzheimer disease[1]. Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways[2]. Epiberberinecan be used for the research of diabetic disease[3].

• Target Antigen:

  Beta-secretase; Cholinesterase (ChE)

• Type:

  Natural Products

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Metabolic Disease; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/Epiberberine.html

• Purity:

  98.46

• Solubility:

  DMSO : 3.33 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  COC1=C(OC)C=C2C(CC[N+]3=C2C=C(C=C4)C(C5=C4OCO5)=C3)=C1

• Molecular Weight:

  336.36

• References & Citations:

  [1]Jung HA, et al. Anti-Alzheimer and antioxidant activities of Coptidis Rhizoma alkaloids. Biol Pharm Bull. 2009 Aug;32(8):1433-8.|[2]Choi JS, et al. Anti-adipogenic effect of epiberberine is mediated by regulation of the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways. Arch Pharm Res. 2015 Dec;38(12):2153-62.|[3]Ma H, et al. Antihyperglycemia and Antihyperlipidemia Effect of Protoberberine Alkaloids From Rhizoma Coptidis in HepG2 Cell and Diabetic KK-Ay Mice. Drug Dev Res. 2016 Jun;77(4):163-70.Aging (Albany NY). 2021 Oct 9;13(19):23193-23209.|J Biomol Struct Dyn. 2022 Dec 29;1-38.|J Ethnopharmacol. 2024 Feb 19:117931.|Molecules. 2024 May 14.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  6873-09-2